Andrew G. Iwach, MD
Associate Clinical Professor
University of California, San Francisco
San Francisco, California
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Andrew G. Iwach, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Belkin Lasers, and OMIC. Shareholder: Eyenovia
Andrew G. Iwach, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Belkin Lasers, and OMIC. Shareholder: Eyenovia
Kuldev Singh, MD, MPH has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aurion, Alcon, Belkin Laser, Centricity, Glaukos, Graybug, Injectsense, Ivantis, Novartis, Olulara Therapeutix, Oculus, Renesxbio, Santen, and Sight Sciences.
Thomas W. Samuelson, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie, Alcon, Allergan, Bausch + Lomb/Valeant, Belkin Vision, ELT Sight, Equinox, Glaukos, Imprimis, Irisvision, Ivantis, Johnson & Johnson Vision, Ocuphire, MicroOptx, New World Medical, PolyActiva, Ripple Therapeutics, Santen, Sight Science, TearClear, Vialase, and Carl Zeiss Meditec. Shareholder: Belkin Vision, Equinox, Ivantis, Ocuphire, Sight Science, Tear Clear, and Vialase.
Ying Han, MD, PhD has no financial relationships with ineligible companies.
Shan Lin, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Iridex Corporation, and Santen Pharmaceuticals. Speakers Bureau: Aerie Pharmaceuticals, Iridex Corporation, and Bausch + Lomb.
Oluwatosin U. Smith, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie, Alcon, Bausch + Lomb, Allergan, Iridex, Santen, New World Medical, and iris Vision. Speakers Bureau: Aerie, Bausch + Lomb, and Allergan. Shareholder: Glaukos, Nova Eye Medical and Olleyes.
Ruth D. Williams, MD has no financial relationships with ineligible companies.
Robert L. Stamper, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Inject Sense and Smartlens.
Mildred M.G. Olivier, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie and AbbVie (Allergan). Speakers Bureau: Bausch + Lomb; Advisory Board: Horizon
Terri Pickering, MD has no financial relationships with ineligible companies
Yvonne Ou, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Oculinea and Janssen. Grant/Research Support: Astellas Institute of Regenerative Medicine
Sunita Radhakrishnan, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Netra Systems
J. Michael Jumper, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: EyeBio. Speakers Bureau: Dutch Ophthalmic Research. Grant/Research Support: Genentech, Novartis, Regeneron, RegenXBio, and Boehringer Ingelheim.
L. Jay Katz has had a financial relationship or affiliation with the following ineligible companies in the form of Speakers Bureau: Allergan, Shareholder: Glaukos, Mati Pharma, Olleyes, and Aerie Pharmaceuticals.
The Evolve and Glaucoma Research and Education Group staff, planners and peer reviewer have no financial relationships with ineligible companies.
